Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2020-03-12

Original market date: See footnote 1

2015-04-28

Product name:

FERRIPROX

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section .

DIN:

02436558

Product Monograph/Veterinary Labelling:

Date: 2020-03-11 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company: 

CHIESI CANADA CORP.
100e-3800 Steeles Avenue West
Woodbridge
Ontario
Canada  L4L 4G9

Class: 

Human

Dosage form(s):

Tablet

Route(s) of administration:

Oral

Number of active ingredient(s):

1

Schedule(s):

Prescription  

Biosimilar Biologic Drug:

No

American Hospital Formulary Service (AHFS): See footnote 3

64:00.00   HEAVY METAL ANTAGONISTS

Anatomical Therapeutic Chemical (ATC): See footnote 4

V03AC02  DEFERIPRONE

Active ingredient group (AIG) number:See footnote 5

0156430003

List of active ingredient(s)
Active ingredient(s) Strength
DEFERIPRONE 1000 MG

Risk Management Plans See footnote 7

A Risk Management Plan (RMP) for this product was submitted.

Additional Risk Minimization Measures
Controlled Distribution Program
Healthcare Professional Education
Patient Education
Patient Wallet Card
Pharmacovigilance/Monitoring Activity
Registry

Application information

Related information

Contact us

Version 3.8.0
Date modified: